Cemiplimab is a PD-1 inhibitor approved for the treatment of patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) who are not eligible for curative surgery or curative radiation therapy.

How to Purchase Cemiplimab

Overseas Purchase

Patients may choose to consult and purchase Cemiplimab at hospital pharmacies or licensed pharmacies in countries/regions where the drug has been launched.

Since drug prices may be affected by factors such as regional differences and exchange rate fluctuations, patients need to make budgetary plans in advance before purchasing.

Purchase via Medical Service Institutions

Patients may consult domestic overseas medical service institutions that cooperate with international pharmacies or pharmaceutical companies.

These institutions can usually provide legal import channels and offer professional consultation and guidance.

Precautions for Purchasing Cemiplimab

Strict Medical Evaluation

A comprehensive evaluation by a professional doctor is mandatory before using the drug.

According to FDA approval information, this drug is indicated for specific types of CSCC patients. It is necessary to confirm that the patient meets the indication criteria: patients with metastatic CSCC or locally advanced CSCC who are not suitable for curative surgery or radiation therapy.

Confirmation of Medication Regimen

The standard recommended dose is 350mg, administered as an intravenous infusion once every 3 weeks, with each infusion lasting 30 minutes.

Before purchase, the specific medication regimen formulated by the doctor (including dose, administration interval, etc.) should be confirmed.

Preparation for Adverse Reaction Monitoring

Cemiplimab may cause immune-related adverse reactions. Before purchase, patients should understand these risks and make preparations for monitoring.

Common adverse reactions include fatigue (29%), rash (25%), and diarrhea (22%). Severe adverse reactions include immune-mediated pneumonia, colitis, hepatitis, and endocrine disorders, which require close monitoring.

Precautions for Special Populations

Contraindicated in pregnant women, as it may cause fetal harm.

Women of childbearing age should use effective contraceptive measures during treatment and for at least 4 months after the last dose.

Lactating women should discontinue breastfeeding during treatment and for 4 months after the last dose.

Methods to Identify Authenticity of Cemiplimab

Package Inspection

Authentic LIBTAYO (brand name of Cemiplimab) is supplied as single-dose vials in two specifications: 350mg/7mL (50mg/mL) and 250mg/5mL (50mg/mL).

The package should be intact and undamaged, with a formal drug approval number and production batch number.

The solution should be a clear or slightly opalescent, colorless to pale yellow liquid, which may contain trace amounts of translucent to white particles.

Label Information Verification

Drug brand name (LIBTAYO) and generic name (cemiplimab-rwlc).

Specification and concentration (e.g., 350mg/7mL).

Storage conditions (refrigerated at 2°C to 8°C).

Manufacturer information (Regeneron Pharmaceuticals, Inc.).

Approval number.

Production batch number and expiration date.

Drug Characteristic Inspection

The drug should be a clear to slightly opalescent, colorless to pale yellow solution.

It may contain trace amounts of translucent to white particles.

If the solution is turbid, discolored, or contains foreign substances other than those mentioned above, it should be discarded and not used.